IKBKG
IKBKG, also known as NEMO or IKK-gamma, is the regulatory subunit of the inhibitor of kappaB kinase (IKK) complex. It activates NF-kappaB, driving expression of genes involved in inflammation, immunity and cell survival. Browse Assay Genie's current range of IKBKG research reagents below, or read on for the biology behind the target.
IKBKG encodes NF-kappa-B essential modulator, universally abbreviated NEMO, the regulatory subunit of the inhibitor of kappaB kinase (IKK) complex. The complex activates NF-kappaB, which in turn switches on genes involved in inflammation, immunity, cell survival and other pathways. As the non-catalytic, regulatory component, NEMO is central to how upstream signals are channelled into NF-kappaB activation. UniProt also notes that it is considered a mediator of NF-kappaB activation by the HTLV-1 Tax oncoprotein during microbial infection.
The human protein is annotated in the cytoplasm and the nucleus. HGNC places the gene in the IKK complex group and in the C2HC NEMO-type zinc finger group. The gene lies on the X chromosome, and a pseudogene highly similar to this locus sits in an adjacent region of the X chromosome, which is worth bearing in mind when designing nucleic acid based assays for the IKBKG gene. Mouse and rat both carry an orthologous gene named Ikbkg.
Many aliases reflect the history of the gene: IKK-gamma, NEMO, Fip3p, FIP-3, FIP3, IKKAP1, IKKG, IP1 and IP2. Earlier HGNC names include incontinentia pigmenti and several forms of inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma. Mutations in the gene result in incontinentia pigmenti, hypohidrotic ectodermal dysplasia and several other types of immunodeficiency, making IKBKG an important subject for researchers studying NF-kappaB signalling and inherited disease.
IKBKG is the regulatory subunit of the IKK complex, which activates NF-kappaB and the genes controlling inflammation, immunity and cell survival.
Mutations in IKBKG cause several types of immunodeficiency, making the protein relevant to studies of immune defects.
Mutations in this gene result in incontinentia pigmenti and hypohidrotic ectodermal dysplasia, providing a focus for developmental disease research.
IKBKG is considered a mediator of HTLV-1 Tax oncoprotein activation of NF-kappaB, linking it to virus-driven signalling studies.
IKBKG encodes the regulatory subunit of the inhibitor of kappaB kinase (IKK) complex. The complex activates NF-kappaB, resulting in activation of genes involved in inflammation, immunity, cell survival and other pathways. It is also considered a mediator of HTLV-1 Tax activation of NF-kappaB.
UniProt names the protein NF-kappa-B essential modulator, abbreviated NEMO. Other aliases include IKK-gamma, IKKG, IKKAP1, Fip3p, FIP-3, FIP3, IP1 and IP2. Earlier HGNC names include incontinentia pigmenti, reflecting the disease linked to mutations in the gene.
Mutations in IKBKG result in incontinentia pigmenti, hypohidrotic ectodermal dysplasia and several other types of immunodeficiency. Mouse and rat each have an orthologue named Ikbkg. Check the datasheet of any product for its validated reactivity.
Other IKK complex members, NF-kappaB pathway proteins and inflammation-signalling targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9Y6K9; product specifications from Assay Genie datasheets.